EUCTR2015-000846-42-SE进行中(未招募)不适用
Effects on re-endothelialisation with Bydureon treatment add on to Insulin versus Insulin alone, both in combination with Metformin in type 2 diabetic subjects (Rebuild Study). - Rebuild study
Stockholm South General Hospital0 个研究点开始时间: 2015年5月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients eligible for PCI with application of DES, due to ACS.
- •2. Patients with known or newly diagnosed T2D (type 2 diabetes is diagnosed according to current WHO criteria or by the use of anti-diabetic drugs)
- •3. Male and female subjects 18-80 years.
- •4. HbA1c (accordingly to IFCC) 47 mmol/mol – 110 mmol/mol.
- •5. Signed informed consent form.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1. Type 1 diabetes (autoantibody positive).
- •2. Any history of receiving GLP-1 analogues or dipeptidyl peptidase inhibitors within 6 months
- •3. Known severe heart failure, classified as NYHA 4.
- •4. Active myocarditis; malfunctioning artificial heart valve.
- •5. History of ventricular tachycardia within 3 months before study entry; second- or third-degree atrioventricular block.
- •6. Supine systolic blood pressure <85 mm Hg or >200 mm Hg at screening
- •7. Primary renal impairment, creatinine clearance < 45 ml/min if treated with metformin.
- •8. Uncorrected hypokalemia or hyperkalemia (potassium <3.5 mmol/l or >5.5 mmol/l).
- •9. Significant anemia (Hb < 90 g/l)
- •10. Severe gastrointestinal disease, including gastroparesis. As judged by the Investigator.
- •11. Body mass index (BMI) > 45 kg/m2.
- •12. Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy in the previous 5 years. Patients with intraepithelial squamous cell carcinoma of the skin treated with topical 5FU and subjects with basal cell skin cancer are allowed to enter the trial.
- •13. Females of child bearing potential who are pregnant, breast-feeding or intend to become pregnant.
- •14. Current drug and alcohol abuse.
- •15. History of acute or chronic pancreatitis
- •16. Subjects considered by the Investigator to be unsuitable for the study
研究者
相似试验
已完成
4 期
Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes SubjectsRestenosisDiabetesAtherosclerosisNCT02621489Karolinska Institutet38
招募中
4 期
Early vessel healing after implantation of a hydrophilicpolymer-coated Zotarolimus-eluting stent. Serial Optical Coherence Tomography study.AnginaJPRN-UMIN000015157Kansai Medical University The second department of internal medicine30
进行中(未招募)
1 期
Evaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment of Pulmonary Hypertension secondary to sarcoidosisPulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and secondary to Sarcoid Patients devolop pulmonary hypertension for various reasons, two common causes are Chronic Obstructive Pulmonary disease and Sarcoid. Once developed it may go on to cause right heart failure and severe breathlessness and eventually death. We believe that the use of bosentan may lower the pulmonary hypertension and improve symptoms.MedDRA version: 8.1 Level: LLT Classification code 10037400 Term: Pulmonary hypertensionEUCTR2006-005361-19-GBSt Georges Hospital45
招募中
2 期
A Study to Assess the Effects of the Endothelin Receptor Antagonist Zibotentan and the SGLT2 Inhibitor Dapagliflozin in Patients elevated Albuminuria: a Randomized Double Blind Cross-Over Trialdiabetic kidney disease1001265310029149diabetic nephropathyNL-OMON54022niversitair Medisch Centrum Groningen12
进行中(未招募)
1 期
A Study to Assess the Effects of the drugs Zibotentan and Dapagliflozin in Patients with Elevated Levels of Protein in UrinePatients with elevated AlbuminuriaMedDRA version: 21.1Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.0Level: PTClassification code 10016807Term: Fluid retentionSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2021-001324-18-NLniversity Medical Center Groningen38
